ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Interleukins"

  • Abstract Number: 0811 • ACR Convergence 2020

    Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab

    Janet Pope1, Amy Praestgaard2, Hubert van Hoogstraten3, Melitza Iglesias-Rodriguez2, Serge Perrot4, Yvonne Lee5, Anthony Sebba6 and Ernest Choy7, 1Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, 2Sanofi, Cambridge, MA, 3Sanofi, Bridgewater, NJ, 4Paris Descartes University, Paris, Ile-de-France, France, 5Northwestern University Feinberg School of Medicine, Chicago, IL, 6Arthritis Associates, Palm Harbor, Tampa, FL, 7CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Prescription opioids are routinely used in patients with RA. However, use of opioids should be minimized to prevent abuse and addiction. Chronic opioid use…
  • Abstract Number: 1224 • ACR Convergence 2020

    Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab

    Esteban Rubio Romero1, Alejandro Muñoz Jiménez2, Rosalia Martinez Perez3 and Lara Mendez Diaz4, 1VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, 2H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, 3Virgen del Rocío University Hospital, seville, Spain, 4Virgen del Rocío Hospital, sevilla, Spain

    Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
  • Abstract Number: 1632 • ACR Convergence 2020

    Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry

    Joerg Henes1, Norbert Blank2, Michael Borte3, Ivan Foeldvari4, Gerd Horneff5, Markus Hufnagel6, Tilmann Kallinich7, Birgit Kortus-Goetze8, Catharina Schuetz9, Frank Weller-Heinemann10, Julia Weber-Arden11 and Jasmin Kuemmerle-Deschner12, 1Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, 2Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, 3ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, 4Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, 5Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 6Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, 7Charite, Berlin, Germany, 8Division of Nephrology, University of Marburg, Germany, Marburg, Germany, 9Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, 10Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, 11Novartis Pharma GmbH, Nuremberg, Germany, 12University Hospital Tuebingen, Tuebingen, Germany

    Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully  treated with the anti-IL-1ß inhibitor canakinumab.…
  • Abstract Number: 0068 • ACR Convergence 2020

    Single Cell RNA-seq to Characterize Monocyte Subtypes in the Autoinflammatory Interferonopathy, SAVI and the Inflammasomopathy, NOMID

    Ying Zhang1, Bernadette Marrero2, Adriana de Jesus3, Sara Alehashemi4, Jinguo Chen5, Rongye Shi6, Huizhi Zhou6, Clifton Dalgard7, Manfred Boehm8 and Raphaela Goldbach-Mansky9, 1Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 2Computational Systems Biology Section/NIAID/NIH, Bethesda, MD, 3Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, 4Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, 5Molecular Immunology Section, National Eye Institute, National Institutes of Health, Bethesda, MD, 6Molecular Immunology Section, National Eye Institute, National Institutes of Health, Bethesda, 7Department of Anatomy, Physiology and Genetics, Uniformed Services University of Health Sciences, Bethesda, 8Center for Molecular Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 9Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD

    Background/Purpose: Monocytes are pivotal producers of key inflammatory cytokines that drive autoinflammatory diseases. In SAVI, constitutive STING activation causes chronic activation with increased type-I IFN…
  • Abstract Number: 0827 • ACR Convergence 2020

    Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis

    Thomas Huizinga1, Ernest Choy2, Amy Praestgaard3, Hubert van Hoogstraten4, Patrick R LaFontaine3, Patricia Guyot5, Daniel Aletaha6, Ulf Müller-Ladner7, Yoshiya Tanaka8, Jeffrey R Curtis9 and Roy Fleischmann10, 1Leiden University Medical Center, Leiden, Netherlands, 2CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 3Sanofi, Cambridge, MA, 4Sanofi, Bridgewater, NJ, 5Sanofi, Chilly-Mazarin, France, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 7Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, 8The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 9Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 10Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
  • Abstract Number: 1225 • ACR Convergence 2020

    Targeting to IL-6 or Specific JAKs for RA Treatment: Seeking a Rationale for Switching Each Other If One of These Treatments Resulted in Lack of Efficacy

    Yoshinobu Koyama1, Yoshiharu Sato2, Hiroshi Iijima2, Moe Sakamoto3 and Toshie Higuchi3, 1Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan, 2DNA Chip Research Inc, Tokyo, Japan, 3Division of Rheumatology, Okayama Red Cross Hospital, Japanese Red Cross Society, Okayama, Japan

    Background/Purpose: Inhibition of IL-6 signaling is one of the most established strategies for RA treatment. Tocilizumab (TCZ) is the pioneer which blocks IL-6 signaling by…
  • Abstract Number: 1824 • ACR Convergence 2020

    Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358

    Christie Fanton1, Richard Furie2, Neha Dixit1, Cat Haglund1, Lin Lu1, Suresh Siddhanti1, Vishala Chindalore3, Robert Levin4, Isam Diab5, Brian Kotzin1 and Jonathan Zalevsky1, 1Nektar Therapeutics, San Francisco, CA, 2Division of Rheumatology, Northwell Health, Great Neck, NY, 3Pinnacle Research Group, Anniston, AL, 4Clinical Research of West Florida, Clearwater, FL, 5Paramount Medical Research and Consulting, Middleburg Heights, OH

    Background/Purpose: Treg dysfunction and impaired IL-2 production have been implicated as key immunological defects in the breakdown of immune self-tolerance in SLE. Low-dose IL-2 can…
  • Abstract Number: 0099 • ACR Convergence 2020

    Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis

    Aleksandra Bukina1 and Anna Mihailova1, 1Rigas Stradins university, Riga, Latvia

    Background/Purpose: Persistent synovitis without known markers such as rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) as well as without genetic markers as HLAB27 is not…
  • Abstract Number: 0832 • ACR Convergence 2020

    PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany

    Eugen Feist1, Peer-Malte Aries2, Silke Zinke3, Harald Burkhardt4, Inka Albrecht5, Oliver Bley5, Michael Obermeier6, Patrizia Sternad7, Martin Welcker7, Cornelia Kühne8, Ann-Dörthe Holst9, Niklas Thomas Baerlecken10 and Hans-Peter Tony11, 1Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 2Rheumatologie im Struenseehaus, Hamburg, Germany, 3Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, 4Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, 5Sanofi Aventis Deutschland GmbH, Berlin, Germany, 6GKM Gesellschaft für Therapieforschung, Munich, Germany, 7MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, 8Outpatient practice, Haldensleben, Germany, 9Outpatient practice, Ludwigslust, Germany, 10Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, 11Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany

    Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…
  • Abstract Number: 1232 • ACR Convergence 2020

    Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)

    Andrea Rubbert Roth1, Daniel Furst*2, Stefano Fiore3, Amy Praestgaard4, Vivian Bykerk5, Clifton Bingham III6 and Christina Charles-Schoeman7, 1Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 2Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, 3Sanofi, Bridgewater, NJ, 4Sanofi, Cambridge, MA, 5Hospital for Special Surgery, New York, NY, 6Johns Hopkins University, Baltimore, MD, 7University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…
  • Abstract Number: 1911 • ACR Convergence 2020

    IL-11 Expression in Systemic Sclerosis Pulmonary Fibroblasts Is Mediated by Caspase-1

    Caya McFalls1 and Carol Artlett1, 1Drexel University College of Medicine, Philadelphia

    Background/Purpose: Interleukin-11 (IL-11) has been shown to be associated with idiopathic pulmonary fibrosis, cardiac and kidney fibrosis. However, conflicting data shows IL-11 can be either…
  • Abstract Number: 0173 • ACR Convergence 2020

    mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice

    Zhengping Huang1, Ying Li2, Alexandra Wactor3, Peter Nigrovic4 and Pui Lee5, 11.Guangdong Second Provincial General Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, BOSTON, MA, 21.Brandeis University;2.Brigham and Women's Hospital, Waltham, MA, 3Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, 51.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA

    Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is potentially life-threatening disease characterized by prolonged fever, systemic inflammation and skin rash in addition to joint inflammation. Aberrant…
  • Abstract Number: 0834 • ACR Convergence 2020

    Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry

    Stefano Fiore1, Lang Chen2, Cassie Clinton2, Huifeng Yun2, Amy Praestgaard3, Kerri Ford3 and Jeffrey R Curtis2, 1Sanofi, Bridgewater, NJ, 2Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Sanofi, Cambridge, MA

    Background/Purpose: Patients with RA who have received multiple biologics or targeted therapies over time tend to have more refractory and more severe disease, which may…
  • Abstract Number: 1234 • ACR Convergence 2020

    Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab

    Ernest Choy1, Vivian Bykerk2, Yvonne Lee3, Gregory St John4, Hubert van Hoogstraten5, Kerri Ford6, Amy Praestgaard6 and Anthony Sebba7, 1CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 2Hospital for Special Surgery, New York, NY, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5Sanofi, Bridgewater, NJ, 6Sanofi, Cambridge, MA, 7Arthritis Associates, Palm Harbor, Tampa, FL

    Background/Purpose: Inflammation is a key driver of pain in rheumatoid arthritis (RA). However, in some patients the level of pain exceeds what would be expected…
  • Abstract Number: 1920 • ACR Convergence 2020

    Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment

    Andrea Rubbert Roth1, Scott Tschuppert2, Thomas Neumann2, Ulf Benecke3, Ian Pirker3 and Johannes von Kempis3, 1Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 2Kantonsspital St Gallen, St.Gallen, Switzerland, 3Kantonspital St Gallen, St. Gallen, Switzerland

    Background/Purpose: Tocilizumab (TCZ) represents a potent new therapeutic principle for patients with GCA, however, data on efficacy and safety in patients who present with visual…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology